<DOC>
	<DOCNO>NCT02928861</DOCNO>
	<brief_summary>The purpose study evaluate whether 18F-FDG PET/CT-based prognostic model diffuse large B-cell lymphoma predict disease progression</brief_summary>
	<brief_title>18F-FDG PET/CT-based Prognostic Model Predicting Outcome Patients With Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>In study investigator develop prognostic model base 18F-FDG PET/CT test ability prognostic value patient DLBCL . PET/CT scan evaluation use liver SUVmax reference . Positive lesion PET indicate SUVmax residue higher threshold ( 1.6 fold liver SUVmax ) new 18F-FDG avid lesion . 18F-FDG PET/CT-based prognostic model include PET/CT image , dominant clinical pathological prognostic factor predict disease progression chemotherapy survival DLBCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1. newly diagnose DLBCL ; 2. treat use anthracyclinecontaining regimen without rituximab ; 3. minimal followup 6 month completion firstline treatment ; 4. complete medical history clinicopathological data 1. secondary malignant disease ; 2. serious infection inflammation ( e.g. , HIV ) ; 3. primary central nervous system lymphoma ; 4. hepatic renal dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Prognosis</keyword>
</DOC>